http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#Head http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#assertion http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#provenance http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#pubinfo http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#assertion http://purl.obolibrary.org/obo/DOID_10933 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_10933 http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00472 http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association http://www.w3.org/2000/01/rdf-schema#label fluoxetine capsules usp are a selective serotonin reuptake inhibitor indicated for acute and maintenance treatment of major depressive disorder mdd in adult and pediatric patients aged 8 to 18 years 1 1 acute and maintenance treatment of obsessive compulsive disorder ocd in adult and pediatric patients aged 7 to 17 years 1 2 acute and maintenance treatment of bulimia nervosa in adult patients 1 3 acute treatment of panic disorder with or without agoraphobia in adult patients 1 4 fluoxetine capsules usp and olanzapine in combination acute treatment of depressive episodes associated with bipolar i disorder in adults 1 5 fluoxetine capsules usp are indicated for the acute and maintenance treatment of major depressive disorder in adult patients and in pediatric patients aged 8 to 18 years see clinical studies 14 1 the usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should periodically be re evaluated see dosage and administration 2 1 fluoxetine capsules usp are indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with obsessive compulsive disorder ocd see clinical studies 14 2 the effectiveness of fluoxetine capsules usp in long term use i e for more than 13 weeks has not been systematically evaluated in placebo controlled trials therefore the physician who elects to use fluoxetine capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration 2 2 fluoxetine capsules usp are indicated for the acute and maintenance treatment of binge eating and vomiting behaviors in adult patients with moderate to severe bulimia nervosa see clinical studies 14 3 the physician who elects to use fluoxetine capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration 2 3 fluoxetine capsules usp are indicated for the acute treatment of panic disorder with or without agoraphobia in adult patients see clinical studies 14 4 the effectiveness of fluoxetine capsules usp in long term use i e for more than 12 weeks has not been established in placebo controlled trials therefore the physician who elects to use fluoxetine capsules usp for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration 2 4 when using fluoxetine capsules usp and olanzapine in combination also refer to the clinical studies section of the package insert for olanzapine and fluoxetine hydrochloride capsules fluoxetine capsules usp and olanzapine in combination is indicated for the acute treatment of depressive episodes associated with bipolar i disorder in adult patients fluoxetine capsules usp monotherapy is not indicated for the treatment of depressive episodes associated with bipolar i disorder http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00472 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#provenance http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#pubinfo http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#sig http://purl.org/nanopub/x/hasSignature aqwx3O5MBt/6UgUtYoLgi7x3tnv2ygQvPXRiDTUG8UPhg/n/1RfkLR7a4k+TKUNaSlaoNeD7NqevVEAeFEWiUbWKygkc8tXNwEA/nAgA0tJWTBbe66Bd6Un4zb+nqXaKvyk2YG7m0yJlW30Ok0b2Jx58fsVQMk9QIPNMpxU2IB8= http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng http://purl.org/dc/terms/created 2021-06-15T18:01:37.131+02:00 http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAuyra2NNN2YUaTM_nAvYaBZlQn4dlXJS6avaXxgINIng https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs